What We're Reading: Page 2
Industry reads hand-picked by our editors
Apr 07, 2021
-
The New York Times
U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted
-
STAT
Troubling podcast puts JAMA, the ‘voice of medicine,’ under fire for its mishandling of race
-
Vanity Fair
“We Are Hoarding”: Why the U.S. Still Can’t Donate COVID-19 Vaccines to Countries in Need
-
Evaluate Vantage
Biotech venture financing starts the year with a bang
Apr 06, 2021
-
The Wall Street Journal
Covid Arsenal Needs Pills as Well as Shots
-
Chemical & Engineering News
IL-2 treatment can be dangerous. Here’s how drug firms are trying to fix it
-
The New York Times
Researchers Are Hatching a Low-Cost Coronavirus Vaccine
Apr 05, 2021
-
Science
Side effect worry grows for AstraZeneca vaccine
-
The Boston Globe
Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level
-
The Wall Street Journal
CEO Transformed Treatment for HIV, Hepatitis
Apr 01, 2021
Mar 31, 2021
-
The Wall Street Journal
Former Senior Merck Executive Hired by Life-Sciences Firm
-
The New York Times
Getting One Vaccine Is Good. How About Mix-and-Match?
-
Evaluate Vantage
Radiotherapeutics remain in the deal-making frame
-
Endpoints News
Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died
Mar 30, 2021
-
The Atlantic
A Terrible Conundrum for the AstraZeneca Vaccine
-
Endpoints News
After dismissing CFO over ‘inappropriate messages,’ Eli Lilly faces new accusations of sexual harassment
-
Axios
The growing fight over coronavirus vaccine patents
-
Reuters
Amarin's heart drug Vazkepa gets European Commission approval
Mar 29, 2021
-
ProPublica
Inside Purdue Pharma's Media Playbook: How It Planted the Opioid 'Anti-Story'
-
Science
A rare clotting disorder may cloud the world's hopes for AstraZeneca's COVID-19 vaccine
-
The Boston Globe
At Mass General Brigham, a sweeping effort to unify hospitals and shed old rivalries
-
CNBC
White House weighs temporarily lifting intellectual property shield on Covid-19 vaccines
-
Evaluate Vantage
Humanigen claims a Covid-19 win with lenzilumab
Previous
